Skip to content

Salarius

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Programs
    • Epigenetics
    • Targeted Protein Degradation
    • Pipeline
    • Publications
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
      • Corporate Governance
      • Committee Composition
    • Press Releases
    • In The News
    • Financial Reports
      • Annual Reports
      • Quarterly & Other Reports
      • Tax Documents
    • SEC Filings
    • Events & Presentations
    • Investor Resources
      • Investor FAQs
      • Information Request
      • E-mail Alerts
      • Contact IR
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
    • Analyst Coverage
  • Contact Us
Search

Archives: News

Jan 13, 2022

Salarius Expands Oncology Pipeline Through Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Aug 11, 2021

David Arthur, Salarius CEO Speaks with Dan Sfera of The Clinical Trials Guru

Aug 4, 2020

Salarius Pharmaceuticals raises millions for expanded clinical trial, moves office in TMC

Jun 19, 2020

15 Biotech Companies in Houston Making a Major Impact on Medicine

Apr 7, 2020

Targeting Epigenetic Causes of Ewing’s Sarcoma with David Arthur Salarius Pharmaceuticals on Empowered Patient Podcast with Karen Jagoda

Jan 15, 2020

Salarius During the JP Morgan Week – Attend the Biotech Showcase Presentation or Join the Live Webcast

Jan 14, 2020

Salarius Pharmaceuticals CEO talks through recent achievements for its lead cancer drug candidate

Jan 9, 2020

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

Dec 11, 2019

Emerging Biopharma Find Ways to Persevere Struggles

Nov 20, 2019

Salarius CEO, David Arthur discusses the future of the company with SNN Network

Posts navigation

Older posts

Recent Posts

  • Salarius Pharmaceuticals to Participate in BIO International Convention 2022
  • Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
  • Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
  • Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
  • Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Recent Comments

    Archives

    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Salarius

    • About Us
      • Overview
      • Leadership Team
      • Board of Directors
      • Scientific Advisors
    • Our Programs
      • Epigenetics
      • Targeted Protein Degradation
      • Pipeline
      • Publications
      • Clinical Trials
    • News & Events
      • Press Releases
      • Events
      • In the News
    • Investors
      • Overview
      • Corporate Governance
      • Press Releases
      • In The News
      • Financial Reports
      • SEC Filings
      • Events & Presentations
      • Investor Resources
      • Stock Information
      • Analyst Coverage
    • Contact Us
    • Like Us on Facebook
    • Follow Us on Twitter
    • Connect on LinkedIn
    © 2022 Salarius Pharmaceuticals, Inc. All Rights Reserved. Privacy and Terms of Use